Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769704 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Phase 3 study of Melanoma, sponsored by BioVex Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 437
- Enrollment target
- 20
- Study locations
NCT00769704 is a Phase 3 study of Melanoma that has completed, run by BioVex Limited. The registered enrollment target is 437 participants, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00769704, a Phase 3 study of Melanoma, has completed, sponsored by BioVex Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 437 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma. The efficacy endpoints of the study aim to demonstrate overall clinical benefit for patients treated with talimogene laherparepvec as compared to GM-CSF.
Conditions Studied
Interventions
- BIOLOGICAL GM-CSF
- BIOLOGICAL Talimogene laherparepvec
Study Locations (20)
Florida
- Baptist Cancer Institute - Jacksonville
- Lakeland Regional Cancer Center - Lakeland
- University of Miami - Miami
- Mount Sinai Medical Center CCOP - Miami Beach
- MD Anderson Cancer Center Orlando - Orlando
- H. Lee Moffitt Cancer Center - Tampa
- Palm Beach Cancer Institute - West Palm Beach
California
- University of California San Diego, Moores Cancer Center - La Jolla
- UCLA Medical Center - Los Angeles
- San Francisco Oncology Associates - San Francisco
- Northern California Melanoma Center, St. Mary's Medical Center - San Francisco
- John Wayne Cancer Institute - Santa Monica
- Redwood Regional Medical Group Inc, North Bay Melanoma Program - Sebastopol
Illinois
- Rush University Medical Center - Chicago
- Cancer Care Center at Lutheran General Hospital - Park Ridge
Arizona
- University of Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Cancer Center - Aurora
Georgia
- Emory University - Atlanta
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769704
The ClinicalTrials.gov registry entry for NCT00769704 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (38% lower). The listed sponsor is BioVex Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which GM-CSF is the first listed.
NCT00769704 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00769704 about?
NCT00769704 is a clinical study titled "Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma". The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma. The efficacy endpoints of the study aim to demonstrate overall clinical b...
What is the current status of trial NCT00769704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2009-04. Estimated completion is 2014-09.
What conditions does trial NCT00769704 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00769704?
The interventions under investigation include: GM-CSF (BIOLOGICAL), Talimogene laherparepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT00769704?
This trial is sponsored by BioVex Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00769704 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.